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Abstract We have cloned and functionally characterized a nov-
el protein, BmVMP30, which is synthesized by the cells of the
follicular epithelium of the ovarian follicles of the domesticated
silkworm Bombyx mori, secreted from them and associated with
the vitelline membrane. BmVMP30 is a 30 kDa protein that
bears limited structural features reminiscent of other insect vi-
telline membrane proteins. Although BmVMP30 does not share
pronounced similarities or signature motifs with other reported
proteins, its temporal and spatial expression and its behavior
throughout oogenesis suggest that it is a novel member of the
insect vitelline membrane protein family. The protein is ex-
pressed exclusively in the cells of the follicular epithelium during
stages 315 to 31 of vitellogenesis, secreted from them and,
ultimately, localized at the junction between the oocyte and
the eggshell, where the vitelline membrane is located. Treatment
of follicles with an antisense oligonucleotide that encompasses
the translation initiation codon results in the production of an
N-terminally truncated protein and disruption of the integrity of
the follicular epithelium. Antisense oligonucleotide treatment,
however, has no e¡ect on the implementation of the develop-
mental program that directs the autonomous progression of
ovarian follicles through the last stages of vitellogenesis and
choriogenesis. + 2002 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Oogenesis in the domesticated silkworm (Bombyx mori) is
characterized by the asynchronous development of follicles
resulting in the formation of linear arrays (ovarioles) of pro-
gressively maturing follicles [1]. Each follicle is a functional
developing unit consisting of three cell types: one oocyte, an
anterior cap-forming cluster of seven nurse cells of germ cell
origin, and a surrounding monolayer of approximately 5000
epithelial (follicular) cells of mesodermal origin [2]. The fol-
licular epithelium can be viewed as an exocrine gland pro-
grammed to secrete unidirectionally (toward the oocyte) the
eggshell components, vitelline membrane (VM) and chorion
[1,3]. As follicles mature, they move through the ovarioles and
undergo successively vitellogenesis (yolk uptake) and chorio-
genesis (eggshell formation). During the last ¢ve days of meta-
morphosis, one follicle in each of the four ovarioles terminates
protein uptake from the hemolymph every 2 to 2.4 h [4], an
event that can be reproduced faithfully by in vitro culturing of
isolated follicles or strings of follicles inside their ovarioles [5].
This fundamental characteristic enables the isolation of fol-
licles at every stage of follicle development.
Ovarian development is triggered by the steroid hormone
20-hydroxy-ecdysone (20E; [6]). Previously, it has been hy-
pothesized that 20E helps to bring the follicles to a critical
developmental stage, where the establishment and implemen-
tation of an autonomous developmental program takes place
[5]. Indeed, a restricted number of pre-choriogenic follicles
cultured in vitro are capable of completing oogenesis auton-
omously [5]. This critical point of autonomous program im-
plementation is currently estimated at vitellogenic stage 335
( ; 5) (I. Linstro«m-Dinne'tz, L. Swevers and K. Iatrou, unpub-
lished results). Thus, follicles more mature than stage 335
( ; 5) can complete vitellogenesis and initiate and complete
choriogenesis in the absence of factors extrinsic to the follicle,
and this suggests that stage-speci¢c regulators must be ex-
pressed in a temporal fashion in order for the follicular cells
to undergo terminal di¡erentiation.
One of the products of follicular cell di¡erentiation is the
VM that lies directly over the oocyte plasma membrane. In
contrast to vertebrates in which the VM is secreted by the
oocyte [7], in insects such as Drosophila and Bombyx, VM
proteins (VMPs) are synthesized by and secreted from the
cells of the follicular epithelium [1,8]. In the silkworm, the
secretion of electron dense material at the follicular cell^oo-
cyte interface at day 3 of pharate-adult development marks
the initial stage of VM formation [2]. During vitellogenesis,
this membrane thickens as electron dense material is added.
When the VM approaches its ¢nal thickness, layers of over-
lapping protein plates (chorion) stack on top of it forming a
water barrier that shields the oocyte from dehydration [1].
Thus far, no components of the silkworm VM have been
analyzed. The present study involves the cloning and func-
tional characterization of a novel protein, BmVMP30, that
appears to be involved in the maintenance of the structural
integrity of the VM and the follicular epithelium. BmVMP30
is expressed exclusively in the epithelium of middle/late vitel-
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logenic follicles and its expression requires a decreased titer of
20E in the hemolymph. The protein accumulates at the fol-
licular epithelium^oocyte interface as well as at the intercel-
lular junctions between follicular cells. Antisense oligonucleo-
tide-mediated inhibition of gene function [9] reveals that
BmVMP30 is involved in the maintenance of the structural
integrity of the follicular epithelium and the adjacent VM
during middle/late vitellogenesis in vitro, but does not play
a regulatory role in the execution of the autonomous program
of follicular cell di¡erentiation (completion of vitellogenesis
and choriogenesis).
2. Materials and methods
2.1. Animals
The silkworm strain used was a hybrid provided by the Forest Pest
Management Institute, Sault Ste-Marie, Canada. Rearing was carried
out on arti¢cial diet (Yakuroto Co., Japan) as previously described
[10].
2.2. Mid-late vitellogenic (M/LV)-RNA-enriched cDNA library
synthesis
Ovarian follicles were lysed in Trizol1 (Gibco-BRL) and total
RNA was extracted according to the manufacturer’s recommenda-
tions. Poly (A)þ RNA was prepared and used to generate double
stranded (ds) cDNA as previously described [11]. cDNA fragments
ranging between 100 and 500 bp were prepared by digestion with AluI
or AluI+RsaI.
To amplify speci¢c ds cDNA populations after a round of subtrac-
tive hybridization (SH; below), the ds cDNA pool derived from pre-/
early vitellogenic follicles (hereafter referred to as ‘driver’ cDNA) was
ligated to a ds EcoRI adaptor, while a ds EcoRV adaptor was ligated
to the digested middle/late vitellogenic ds cDNA (hereafter referred to
as ‘tracer’ cDNA) [11].
2.3. Subtractive hybridization
Photobiotinylation of the driver cDNA was carried out as previ-
ously described [12]. Fifty Wg of biotinylated driver was hybridized
with 2.5 Wg of polymerase chain reaction (PCR)-ampli¢ed tracer in 20
Wl of hybridization bu¡er [0.75 M NaCl; 25 mM HEPES, pH 7.3;
5 mM EDTA; 0.1% sodium dodecyl sulfate (SDS)] at 68‡C for 20 h.
After hybridization, 130 Wl of HEPES bu¡er was added, and the
reaction was incubated for an additional 5 min at 68‡C prior to cool-
ing down to room temperature. One hundred and ¢fty Wl of strepta-
vidin-coated magnetic beads (Magnespheres1 ; Promega) in 2U bind-
ing bu¡er (2 M NaCl; 10 mM Tris^HCl, pH 7.5; 1 mM EDTA) were
added to remove the biotinylated nucleic acid. After several rounds of
addition and removal of Magnespheres, the tracer cDNA underwent
another short hybridization to 50 Wg of biotinylated driver, incubation
with Magnespheres1 and removal of the beads. One set of long (20 h)
and short (2 h) hybridizations was considered as one round of SH
[11].
To prepare for the next round of SH, 10% of the subtracted tracer
cDNA was ampli¢ed by PCR. PCR-ampli¢ed tracer recovered after
three rounds of SH was digested with EcoRV and subsequently cloned
into the corresponding site of the pBluescript/SKþ vector (Stratagene)
to yield the M/LV-RNA-enriched cDNA library.
2.4. Di¡erential screening of the M/LV-RNA-enriched cDNA library
After plating of the M/LV-RNA-enriched cDNA library, double
bacterial lifts were prepared [13] and hybridizations were carried out
as described [14] using 32P-labeled tracer or driver cDNA as probes.
Autoradiograms of membranes probed with the tracer DNA were
superimposed over those probed with driver cDNA. Colonies with
tracer-speci¢c signals were reampli¢ed from the template membranes
and inserts were isolated by PCR using T7 and T3 primers (Invitro-
gen).
2.5. Cloning of BmVMP30 cDNA
From a bacterial clone isolated from the M/LV-enriched cDNA
library, a 32P-labeled PCR probe was prepared using T7 and T3
pBluescript1 primers [15]. This radio-labeled probe was used to
screen a total vitellogenic Vgt11 phage cDNA library from B. mori
follicular cells as described [10]. The inserts of two overlapping phage
clones that, in combination, reconstitute the full BmVMP30 open
reading frame (ORF), were cloned as NotI fragments into pBlue-
script/SKþ.
2.6. DNA sequencing
PCR dideoxynucleotide sequencing was carried out using ds DNA
and the ABI Prism Dye Terminator Cycle Sequencing Ready Reac-
tion Kit1 (Perkin-Elmer Corp.). Sequences were analyzed using
DNASIS1 sequence analysis software (Hitachi Software Engineering
Co., Ltd, 1993).
2.7. Inverse PCR
Ten Wg of B. mori genomic DNA, isolated from silk glands as
previously described [16], was digested with HindIII. One hundred
ng of HindIII digested DNA was self-ligated and 10% of the reaction
was subsequently ampli¢ed by PCR using two divergently oriented
BmVMP30 cDNA-speci¢c primers:
RP1 (5P-GTCGGAAACTGAGCCATGACCGGG-3P) and
FP1 (5P-CGTCACTGTTTGGTGGTTGTGGAG-3P for 35 cycles
(1 min at 94‡C, 1 min at 60‡C and 4 min at 72‡C). The PCR product
was cloned into the EcoRV site of pBluescript/SKþ.
2.8. Northern blot analysis
Northern blot analysis was carried out as described [14]. Hybridi-
zation probes were a 0.8 kbp PCR fragment corresponding to the
BmVMP30 ORF, a 0.8 kbp PstI/XhoI digest of A3 actin gene encom-
passing the C-terminal part of the ORF and the 3PUTR portion of its
mRNA [17], and a fragment corresponding to the 28S rRNA gene
prepared from plasmid pBmR161 as described [18].
2.9. Whole mount in situ hybridization
Whole mount in situ hybridization of silkmoth ovarioles using di-
goxigenin-labeled RNA probes was carried out as described [6]. After
hybridization and incubation with anti-digoxigenin HRP-coupled
antibodies, digoxigenin-labeled RNA duplexes were detected by di-
aminobenzidine staining. After color development, the ovarioles were
washed in phosphate-bu¡ered saline (PBS), dehydrated in successive
ethanol baths, mounted in Permount (Fisher Scienti¢c) and examined
using a Zeiss IM35 inverted microscope.
To generate digoxigenin-labeled riboprobes, plasmid DNA contain-
ing a PCR fragment representing 980 bp of BmVMP30 cDNA cloned
into the EcoRV site of its polylinker was linearized with either A£II
(for antisense probe) or BglII (for sense probe) and used as template
for in vitro transcription reactions in the presence of digoxigenin-11-
UTP (Boehringer Mannheim) using T7 or T3 RNA polymerase (Phar-
macia) according to the manufacturer’s recommendations (Boehringer
Mannheim). After synthesis, the sizes of the riboprobes were reduced
to approximately 100 nt by alkaline hydrolysis [19].
2.10. Antibody generation and a⁄nity puri¢cation
A portion of BmVMP30 cDNA £anked by the restriction enzymes
BstBI and EcoRI (from AA 39 until 146) was cloned in frame with the
bacterial glutathione-S-transferase (GST) ORF in pGEX 5X-3 (Phar-
macia) and overexpressed in E. coli XL-1 Blue cells. The GST-
BmVMP30/BstBI-EcoRI fusion protein was subsequently puri¢ed on
glutathione-S-sepharose beads (Pharmacia) and V300 Wg were used
to immunize rabbits (New Zealand White females, Riemans). The
collected polyclonal antiserum was pre-adsorbed twice for 2 h at
4‡C over an A⁄-gel 101-GST slurry to remove anti-GST antibodies
and the supernatant was subsequently passed over an A⁄-gel 101-
GST-BmVMP30 column to isolate BmVMP30 speci¢c antibodies. The
column was extensively washed and speci¢c antibodies were eluted in
acidic elution bu¡er (0.5% acetic acid, 0.15 M NaCl) prior to neutral-
ization with 0.75 volume of 1 M Tris^HCl, pH 9.
To prepare antibody a⁄nity puri¢cation columns, puri¢ed GST
and GST fusion proteins were dialyzed against coupling bu¡er
(0.1 M MOPS pH 7.5) and 20^30 mg of protein were mixed with
1 ml of A⁄-Gel 101 (BioRad) in a maximum volume of 4.5 ml of
coupling bu¡er. The coupling reaction was carried out for 4 h at room
temperature and the A⁄-gel 101 was collected by low speed centri-
fugation. Two hundred Wl of 1 M ethanolamine pH 8 was added to
block active esters prior to washing with 10 volumes of Tris-bu¡ered
saline (TBS: 20 mM Tris pH 7.5, 0.5 M NaCl). One ml A⁄-gel1
columns were stored at 4‡C in TBS containing 0.02% w/v Na-azide.
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2.11. Tissue fractionation and Western blot analysis
Follicular cell protein extracts were generated from follicles resus-
pended in 5 Wl/follicle of cracking bu¡er [125 mM Tris (pH 6.8), 5% L-
mercaptoethanol, 2% SDS and 4 M urea]. After gentle rocking to
prevent oocyte lysis, the supernatant was removed and processed
for SDS^polyacrylamide gel electrophoresis (PAGE). The residual
oocyte fraction was also pelleted and homogenized to obtain the oo-
cyte fraction of the follicles. Other tissues were homogenized in ice
cold PBS prior to being processed for SDS^PAGE.
To isolate eggshells, choriogenic follicles or oviposited eggs were cut
in two and washed extensively in PBS to remove the oocyte content.
To separate the VMs from the chorion, egg shells were suspended in
95% ethanol and vortexed for 30 s to 1 min. VMs (£occulent material
remaining in suspension while the chorion sediments at the bottom of
the tube) were recovered manually.
Chorion solubilization was performed in 50 mM Tris^HCl (pH 9),
8 M Urea, 0.07 M dithiothreitol (DTT), 1.5 mM EDTA and 1.5 mM
lysine for 3 h at room temperature followed by addition of iodo-
acetamide and Tris^HCl, pH 8.4, to ¢nal concentrations of 0.33
and 0.4 M, respectively. After 15 min of incubation in the dark, the
reaction was terminated by addition of L-mercaptoethanol to a ¢nal
concentration of 1.43 M and the samples were prepared for PAGE.
Proteins were processed for ECL1Western blotting as described by
the manufacturer (Amersham). In Western blots, the BmVMP30 anti-
bodies were used at a 1:5000 dilution while the chorion antibodies [20]
were used at 1:1000.
2.12. Immunoprecipitation
Follicles were freshly dissected out from day 5 pupae in ice-cold
homogenizing bu¡er (25 mM HEPES; 0.14 M NaCl; 5.7 M KCl, pH
7.4) containing 2 mM phenylmethylsulfonyl £uoride (PMSF, Sigma)
and 250 mM sucrose. The follicles were resuspended in lysis bu¡er [50
mM Tris, pH 8; 150 mM NaCl; 2 mM PMSF and 10 Wg/ml aprotinin
(Sigma)] and homogenized on ice. The insoluble fraction was pelleted
at 14 000 rpm and resuspended in lysis bu¡er before the addition of
Triton X-100 to a ¢nal concentration of 0.2%. After mixing for 15
min at 4‡C, the second insoluble fraction was pelleted by centrifuga-
tion at 14 000 rpm for 15 min. The supernatant was pre-cleared using
10 Wl of rabbit pre-immune serum and 100 Wl of 50% protein A aga-
rose bead slurry (Upstate Biotechnology Inc.) pre-washed in 50 mM
Tris, pH 8. Immunoprecipitation was carried out using 1 Wl (1/500
¢nal dilution) of a⁄nity puri¢ed anti-BmVMP30 antibody in the pres-
ence of 100 Wl of 50% protein A agarose bead slurry. After incubation
at 4‡C overnight under constant rotation, the beads were removed by
low speed centrifugation and washed three times for 10 min in lysis
bu¡er containing 0.2% v/v Triton X-100. The beads were subsequently
resuspended in 50 Wl of electrophoresis bu¡er and directly loaded on a
SDS^PAGE.
2.13. Whole mount immunocytochemistry
Whole mount immunocytochemistry of silkmoth ovarioles was car-
ried out as described [21]. To detect BmVMP30, samples were ¢rst
incubated overnight with a 1:1000 dilution of BmVMP30 antibody at
4‡C. Incubations with secondary antibody (1:1000 dilution of Cy3-
labeled donkey anti-rabbit antibody (Jackson Immuno-Research Lab.,
Inc.) were also carried out overnight at 4‡C. Tubulin staining was
carried out using mouse anti-Drosophila tubulin antibodies at
1:1000 in combination with £uorescein-labeled anti-mouse antibodies
(at 1:1000; Jackson Immuno-Research Lab., Inc.) in similar fashion
as for BmVMP30. Whole follicles were analyzed under a confocal
Leica DMRE £uorescent microscope at 526 nm and the digital images
were recorded and processed using the Princeton Image acquisition
software and Adobe Photoshop 5.0, respectively.
2.14. Antisense oligonucleotide inhibition assays
Vitellogenic follicles (stage 320) were dissected from a day 5 pupa
and incubated in 14 Wl/follicle of Grace’s medium (Gibco-BRL) con-
taining 0.5% fetal calf serum and 50 Wg/ml gentamycin (Gibco-BRL)
under 100% oxygen atmosphere as described [5], with constant
amounts of oligonucleotide. After three days, follicles were collected
and processed for light or £uorescence microscopy and/or Western
blot analysis.
Fully phosphorothioated oligonucleotides with the sequences 5P-
CCTTACAGAGCAGTTCCATT-3P (AS-Met1), 5P-TTACCTTGAC-
GAGACATTCC-3P (inverse) and 5P-GGCATAGCGTTTGAATT-
TGTGTTGGG-3P (AS-Met4) were synthesized by the Core DNA
Service, University of Calgary, Canada. Oligonucleotides AS-Met1
and AS-Met4 encompass and extend 15 bases downstream of the ¢rst
and fourth ATG codon, respectively, of the BmVMP30 ORF. The
inverse oligonucleotide corresponds to the inverted sequence of AS-
Met1 and was used as a control for speci¢city.
3. Results
3.1. Cloning and characterization of BmVMP30
To isolate cDNAs that are expressed speci¢cally during
middle/late vitellogenesis, the M/LV-enriched cDNA library
was di¡erentially screened using 32P-labeled cDNA probes
obtained from early and middle/late vitellogenic follicles
(stages earlier than 340 and 330 to 31, respectively). Colo-
nies hybridizing only to the middle/late vitellogenic probe
were isolated and their inserts analyzed by sequencing. After
con¢rmation of the stage speci¢city and removal of clones
containing cDNA sequences that encode the yolk protein pro-
duced by the follicular cells (ESP protein; [22]) [23], 74 se-
quences were obtained of which three corresponded to a novel
protein (BmVMP30) which is described here.
To obtain full-length BmVMP30 cDNA, a phage cDNA
library generated from silkmoth follicular cell mRNA [10]
was screened using as probe the partial cDNA sequences ob-
tained from the subtractive library. Two overlapping cDNA
clones were isolated, the longest of which contained a 819 bp
complete ORF. This cDNA also contained 119 nucleotides
(nt) of 3P untranslated (UTR) and a 5P UTR of 11 nt harbor-
ing two in-frame stop codons (GenBank accession number AF
294885; Fig. 1).
To obtain extended 5P and 3P UTR and £anking sequences
of BmVMP30 mRNA, inverse PCR experiments were carried
out using as template self-ligated genomic DNA. Using this
strategy, a 2.5 kb ampli¢cation product was isolated whose
sequences contained the 5P and 3P ends of the cloned cDNA
sequences and adjacent sequences in genomic DNA. Parallel
PCR ampli¢cation of genomic DNA using primers that were
derived from the two ends of the available cDNA clone re-
Fig. 1. Structure of BmVMP30 gene. The structure presented is
compiled from the cDNA clones isolated from the vitellogenic
cDNA library and the genomic fragment obtained by inverse PCR
(GenBank accession number AF 294885; 1456 nt). The transcription
start and polyadenylation sites are indicated by a bended arrow and
an arrow above and below the map, respectively. In the transcribed
sequences, the ORF is displayed as a box while the 5P and 3PUTR
sequences are shown by a black line. Note that the BmVMP30 gene
is intronless. The 5P- and 3P-£anking gene sequences (upstream of
transcription start site and downstream of polyadenylation site) that
were cloned by inverse PCR are also shown by the black line. In
the ORF, two C-terminal hydrophobic domains (22^23 AA) and a
23 AA N-terminal region believed to have a signal peptide-like
function are highlighted as cross-hatched boxes. Indicated are also
the BstBI and EcoRI restriction sites that £ank the most hydrophilic
region (108 AA) of the BmVMP30 ORF used to generate anti-
BmVMP30 antibodies. The position of the sequences complementary
to the phosphorothioated antisense oligonucleotides AS-Met1 and
AS-Met4 used in the antisense inhibition studies is also indicated.
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vealed that the BmVMP30 gene does not contain any intronic
sequences interrupting the cloned cDNA portion (data not
shown). Therefore, the additional sequences acquired by in-
verse PCR represent additional 5P UTR and promoter sequen-
ces of the BmVMP30 gene at the 5P end as well as additional
3P UTR and 3P gene £anking at the 3P end (GenBank acces-
sion number AF 294885; Fig. 1).
The conceptual protein encoded by the BmVMP30 ORF
has a predicted mass of 30.1 kDa. Two C-terminal hydropho-
bic domains of 23 and 22 amino acids, separated by a stretch
of 22 hydrophilic residues, are prominent features of the pro-
tein. A third hydrophobic region was also found at the N-
terminus of the conceptually translated protein and likely rep-
resents a signal peptide sequence (Fig. 1).
3.2. Developmental pro¢les of BmVMP30 mRNA
The accumulation pattern of BmVMP30 mRNA in ovarian
follicles was analyzed by Northern hybridization using as
Fig. 2. Developmental pro¢les of BmVMP30 mRNA. A: Northern blot analysis of BmVMP30 (P30) mRNA expression in staged ovarian fol-
licles during normal development (left) or derived from RH-5992-treated pupae (right). Follicular stages are numbered according to the begin-
ning of choriogenesis (+1; Swevers and Iatrou [5]) in the left panel or numbered according to the terminal (arrested) follicle (t; Swevers and Ia-
trou [6]) in the right panel. Developmental periods of vitellogenesis (early-middle-late) and choriogenesis as well as the MW of the hybridizing
mRNA species are indicated. B: Localization of BmVMP30 mRNA in whole follicles by in situ hybridization. Follicles were hybridized to anti-
sense (panels 1, 3 and 4) or sense (panel 2) digoxigenin-labeled BmVMP30 RNA probes and stained for hybridization signals. Numbers indicate
the developmental stages of the relevant follicles: (3) refers to vitellogenic follicles; (+) refers to choriogenic ones; nc, nurse cells; lv, late vitel-
logenic follicle; c, choriogenic follicle. C: Tissue speci¢city of BmVMP30 (P30) mRNA expression as determined by Northern blot analysis.
Control hybridizations were carried out using a probe speci¢c to 28S rRNA.
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probes RNA isolated from pools of 5^10 follicles along the
developing ovariole (Fig. 2A, left panel). The developmental
blot revealed that BmVMP30 mRNA is not present in the
follicles during early and middle vitellogenesis but appears
during the late vitellogenic period (follicle stages 315 to
31). The peak of accumulation occurs at stages 36/310,
and the mRNA levels decline at the end of vitellogenesis
(stages 31/35). During choriogenesis, BmVMP30 mRNA is
undetectable.
In situ hybridization experiments were carried out to iden-
tify the ovarian cell type in which BmVMP30 gene expression
occurs. As shown in Fig. 2B, BmVMP30 mRNA is present
only in the cells of the follicular epithelium but not in the
nurse cells. Interestingly, BmVMP30 mRNA appears to be
con¢ned to a relatively narrow cytoplasmic ring surrounding
the nuclei of the follicular cells (Fig. 2B, panel 4) rather than
being uniformly distributed throughout the cytoplasm, as ob-
served for other follicular cell-speci¢c mRNAs [6]. The in situ
hybridization experiments also con¢rmed the developmental
pro¢le that was revealed through Northern blot analysis. Dur-
ing vitellogenic period 312 to 39, BmVMP30 mRNA levels
are low but they increase sharply during stages 38 to 36.
BmVMP30 mRNA declines during the last stages of vitello-
genesis and is completely absent from choriogenic follicles
(Fig. 2B, panel 1). No speci¢c signals were obtained with
the BmVMP30 sense RNA probe (Fig. 2B, panel 2).
To deduce the tissue distribution of BmVMP30 mRNA,
Northern hybridizations were carried out using RNA ob-
tained from tissues dissected from day 2 and day 5^6 male
and female pharate adults, which have high and low ecdyste-
roid titers, respectively, in their hemolymph [21] (Fig. 2C).
BmVMP30 mRNA is undetectable in all examined tissues of
day 2 pupae, including ovaries (whose follicles have not yet
attained middle vitellogenesis). This contrasts the situation
with ovaries of day 5^6 females where a strong 1.1 kb hybrid-
izing mRNA band is detected in ovarian tissue. During the
same period, no BmVMP30 mRNA is detectable in any of the
other tissues examined, including brain, testes, epidermis, fat
Fig. 3. Developmental pro¢les of BmVMP30 protein. A: Western blot analysis using BmVMP30 antibodies showing ovary-speci¢c expression
of BmVMP30 protein (arrow). Tissues are derived from day 5^6 pupae. MW markers are indicated on the left. B: Western blot analysis of the
subfollicular distribution of BmVMP30 protein (arrow) during oogenesis using as probe anti-BmVMP30 antibodies. Follicular cell extracts de-
rived from late vitellogenic, early choriogenic or mixtures of late vitellogenic and early choriogenic follicles (lanes P and S) were immunopreci-
pitated using anti-BmVMP30 or anti-GST antibodies, as indicated, followed by Western blot analysis using anti-BmVMP30 antibodies. Abbre-
viations: F, follicular cell extracts; O, oocyte extracts; E, solubilized eggshell ; P and S, immunoprecipitate and supernatant, respectively,
obtained by GST-antibodies. C: Localization of BmVMP30 protein in the inter-follicular cell spaces of a late vitellogenic follicle (top view).
DAPI-staining (1) is shown in blue, while anti-tubulin (2) and anti-BmVMP30 (3) immuno£uorescence is in green and red, respectively. Panel 4
shows an overlay of all the £uorescent signals. D: Western blot analysis of BmVMP30 protein (arrow) expression in solubilized eggshells of
choriogenic follicles and mature eggs after ovulation and oviposition. Oviposited eggs were obtained from mated (‘fertilized’) or non-mated
(‘unfertilized’) females. The 70 kDa BmVMP30 complex that exists in the extract from choriogenic follicles is also indicated by an arrow and
asterisk. Abbreviation: PO=post-oviposition. MW markers are indicated on the left.
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body and gut (Fig. 2C). Thus, BmVMP30 mRNA is expressed
exclusively in ovarian tissue during pharate adult development
when ecdysteroid titers are declining in the hemolymph.
Ovarian development in the silkmoth is induced by 20E at
the beginning of pupation [24]. To investigate in more detail
the hormonal control of BmVMP30 gene expression during
oogenesis, the accumulation pattern of BmVMP30 mRNA in
ovarioles-treated with the non-steroidal 20E-agonist RH-5992
was examined (Fig. 2A, right panel). Although RH-5992 in-
duces the early phases of the ecdysone response in a similar
fashion as 20E, the RH-5992-induced response is not sus-
tained. Because of this, the expression of genes requiring a
decline in hormone titer for induction is suppressed and a
developmental arrest ensues [25]. Injection of RH-5992 into
ligated silkmoth pupal abdomens induces ovarian follicle de-
velopment (initiation of vitellogenesis) but is followed by a
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developmental arrest at mid-vitellogenesis (around stage 320;
[24]). As shown in Fig. 2A (right panel), no BmVMP30
mRNA accumulates in ovarioles induced by RH-5992, sug-
gesting that the expression of BmVMP30 during late vitello-
genesis requires the absence of active 20E signaling in the
follicles.
3.3. Developmental pro¢les of BmVMP30 protein
To examine the tissue distribution and expression patterns
of BmVMP30, polyclonal antibodies raised against it were
used in Western blot and immunocytochemistry studies. In
Western blots of extracts prepared from various tissues of
female pharate adults (day 5^6 pupae), a single protein
band of an approximate mass of 32 kDa was detected in
ovarian extracts, while no signals were detectable in the ex-
tracts obtained from the epidermis, gut or fat body (Fig. 3A).
When extracts prepared from developing follicles were exam-
ined, the 32 kDa polypeptide was found to be present in late
vitellogenic follicular cell extracts (stages 317 to 31; Fig. 3B)
but absent from follicular cells of early choriogenic follicles
(stages +1 to +10). The presence of BmVMP30 in follicular
cell extracts of late vitellogenic follicles and its absence from
the extracts obtained from the follicular cells of choriogenic
follicles is in agreement with the accumulation patterns of
BmVMP30 mRNA (Fig. 2A).
Despite the absence of BmVMP30 protein (and mRNA)
from the cells of the follicular epithelium during choriogenesis
(mild conditions of protein extraction), the presence of the 32
kDa protein was evident in the solubilized eggshells (harsh
conditions of protein extraction) of choriogenic and ovulated
follicles as well as in those of unfertilized eggs (Fig. 3B,D). By
contrast, only minor BmVMP30 immunoreactivity was found
in oocyte extracts, probably resulting from contaminating
eggshell fragments (Fig. 3B, lane 5). Thus, it appears that,
as oogenesis progresses, BmVMP30 is secreted by the follicu-
lar epithelium towards the oocyte and forms part of the egg-
shell structure which includes the VM and the chorion. When
VMs were mechanically dissociated from the chorion of ovu-
lated eggs and subjected to Western blot analysis, both the
VM and the chorion fractions were found to contain
BmVMP30 protein (data not shown).
In the chorion fraction, new immunoprecipitable proteins,
of approximate sizes 70 and 150 kDa, were also detected (Fig.
3D). Attempts to remove the latter by increasing the concen-
tration of reducing agent and incubation time were unsuccess-
ful (data not shown). Thus, the slow-migrating complexes
may result from the cross-linking of BmVMP30 to eggshell
components, presumably chorion proteins. In contrast, two-
dimensional SDS^PAGE analysis of follicular cell proteins of
middle/late vitellogenic follicles, in which the ¢rst dimension
was run in the absence of L-mercaptoethanol and the second
one after reduction, has shown that BmVMP30 can form
higher order complexes that are completely dissociated to
monomer sizes in the second dimension (data not shown).
Presumably, these complexes involve disul¢de bridge forma-
tion and BmVMP30 becomes more permanently cross-linked
during chorion formation.
Upon fertilization, a drastic decrease was observed in the
amount of eggshell BmVMP30 at 12 h post-oviposition (PO)
with BmVMP30 becoming undetectable by 48 h PO and in
diapausing eggs (Fig. 3D). By contrast, this decrease in
BmVMP30 protein was not observed in unfertilized eggs.
Finally, immunocytochemistry localization studies showed
that BmVMP30 is localized in middle/late vitellogenic follicles
at the junction between the follicular epithelium and the oo-
cyte (Fig. 4E, panel 3). Confocal microscopy using Cy3-la-
beled secondary antibodies enabled the localization of this
protein in the intercellular spaces between neighboring follic-
ular cells and at the follicular cell^oocyte interface (Figs. 3C
and 4E, panel 3). When the follicular epithelium is viewed
perpendicular to the follicle surface and the optical section
is at the middle of the columnar follicular cells, a punctate
pattern of BmVMP30 staining is observed (Fig. 3C). Thus,
BmVMP30 appears to be secreted at the lateral membranes
of the follicular cells but not on the entire lateral surface. It is
known that the follicular cells are attached to each other
through cell^cell adhesion junctions but that spaces exist,
through which proteins can reach the oocyte surface from
the hemolymph (e.g. vitellogenin) [26]. The punctate pattern
at this optical section can therefore be explained by assuming
that BmVMP30 is secreted in the discrete lateral spaces be-
tween the follicular cells. At the apical side of the follicular
cells and when viewed tangentially to the oocyte surface, on
the other hand, a uniform staining pattern is observed (Fig.
6
Fig. 4. E¡ects of antisense oligonucleotides on BmVMP30 expression and function in vitro. A: Western blot demonstrating the e¡ects of di¡er-
ent concentrations (2.5 to 20 WM) of BmVMP30 antisense oligonucleotide (AS-Met1) on BmVMP30 (P30) protein expression after in vitro cul-
ture of middle/late vitellogenic follicles (stage 320) for 48 h. No BmVMP30 was initially detected in mid-vitellogenic follicle 320 (rightmost
lane). Arrows point to truncated BmVMP30 proteins presumed to originate from the use of alternative translation start sites; ‘v’ indicates the
presence of 21 kDa vBmVMP30 protein. The presence of BmGATAL (55 kDa) was also assessed on the same blot using BmGATAL N-termi-
nal antibodies [38]. Note that this antiserum recognizes an additional unknown V70 kDa protein in 320 follicles (star). Abbreviation: C, con-
trol 320 follicles cultured in vitro for 48 h in the absence of antisense oligonucleotide. Molecular weight markers are indicated at right. B:
Western blot demonstrating the e¡ects of 15 WM of antisense or inverse oligonucleotide on BmVMP30 (P30) (left), BmGATAL (middle) or cho-
rion protein (right) expression after in vitro culture of middle/late vitellogenic follicles (stage 320) for 48 h. The presence of BmVMP30,
vBmVMP30 (v) and BmGATAL proteins are indicated by arrowheads while the di¡erent chorion protein families (A, B, C) are indicated by
bars. Numbers refer to molecular weights (kDa) of protein markers. C: Northern blot analysis demonstrating the e¡ects of 15 WM of antisense
(AS-Met1) or inverse oligonucleotide on BmVMP30 (P30) and actin mRNA expression after in vitro culture of middle/late vitellogenic follicles
(stage 320) for 48 h. The speci¢c reduction of BmVMP30 mRNA by antisense oligonucleotide treatment is indicated by an arrow. RNA MW
markers are indicated on the left. D: Light microscopy observations of the integrity of the follicular epithelium and the oocyte of developing
follicles following treatment with 15 WM of antisense oligonucleotide (1^3) or inverse oligonucleotide (4 and 5) or without treatment (6 and 7)
for 48 h in vitro. Note the abnormal distribution of the yolk within the antisense oligonucleotide-treated follicles (white arrow in 3). E: Fluo-
rescence microscopy observations of the integrity of the follicular epithelium and the oocyte of developing follicles following treatment with 15
WM of antisense oligonucleotide (2, 4, 6) or inverse oligonucleotide (1, 3, 5) for 48 h in vitro. Follicles were stained with DAPI (1 and 2) or
stained with £uorescent anti-BmVMP30 (3 and 4) or anti-tubulin (5 and 6) antibody complexes. Note the disruption of the follicular epithelium
characterized by gaps in the nuclei staining (2), di¡use localization of BmVMP30 epitopes within the follicular cells (4) and a non-homogeneous
tubulin staining (6). The presumed location of BmVMP30 and the vitelline membrane is marked by a white arrow in 3 (bar= 50 Wm).
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4E, panel 3). Co-localization studies using anti-tubulin anti-
bodies (to stain the cytoplasm of the follicular cells) and
DAPI (to stain the nuclei) con¢rm that BmVMP30 is concen-
trated at the intercellular junction between three or four fol-
licular cells and not throughout the cytoplasm of the epithelial
cells (Fig. 3C).
3.4. Analysis of BmVMP30 function during oogenesis
To analyze the function of BmVMP30 during oogenesis, the
approach of antisense oligodeoxynucleotide-mediated inhibi-
tion of gene expression was employed [9]. Antisense (AS-
Met1) and control inverse phosphorothioated oligonucleotides
were designed that encompassed the mRNA region containing
the translation initiation codon for BmVMP30 (Fig. 1). In an
attempt to block the translation of endogenous BmVMP30,
follicles at vitellogenic stage 320 were incubated for 48 h in
vitro (i.e. a time period that allows the follicles to enter cho-
riogenesis) with various concentrations of the AS-Met1 oligo-
nucleotide. The viability of the follicles was assessed by ana-
lyzing the incorporation of 35S-labeled methionine into
protein. Concentrations of 20 WM were found to be toxic,
while at 15 WM there was signi¢cant incorporation of radio-
activity into protein that was comparable to control follicles.
The impact of increasing amounts of phosphorothioated
antisense oligonucleotide on BmVMP30 protein expression
was assessed by Western blot. When the concentration of
AS-Met1 increased from 2.5 to 20 WM, the amounts of full-
length BmVMP30 protein diminished and reached undetect-
able levels at 15 WM (Fig. 4A,B). Concomitantly, a 21 kDa
protein that is recognized by the antibodies appeared
(vBmVMP30) whose accumulation was proportional to the
increase in the concentration of AS-Met1.
The accumulation of vBmVMP30 (Fig. 4A,B) may be ex-
plained by the usage of an internal ATG start codon, down-
stream of the ¢rst site that is putatively blocked by the anti-
sense oligonucleotide. In contrast to the disruption of
BmVMP30 protein accumulation, the expression of the cho-
rion gene regulator BmGATAL (M. Lunke and K. I., unpub-
lished results ; [14]) was not adversely a¡ected by the presence
of oligonucleotide in the culture medium (Fig. 4A,B).
Attempts to reproduce these results in vivo were unsuccess-
ful (data not shown), because the daily injection of antisense
oligonucleotides at the optimal concentration mentioned
above yielded no inhibition of BmVMP30 expression and no
noticeable phenotype (see also further below). Presumably in
vivo injected oligonucleotides are rapidly cleared from the
hemolymph by non-ovarian tissues such as fat body and Mal-
pighian tubules and only limited amounts may be taken up by
the developing follicles.
When the inverse oligonucleotide was used at similar con-
centrations as AS-Met1, no truncated BmVMP30 protein was
detected in Western blot analysis (Fig. 4B, left). We noted,
however, that the amount of full-length BmVMP30 was re-
duced upon treatment with inverse oligonucleotide at high
concentration (15 WM; Fig. 4B, left) and therefore cannot
rule out a slightly toxic e¡ect of phosphorothioated oligonu-
cleotides on in vitro cultured follicles. It is possible that the
addition of phosphorothioated oligonucleotide in the medium
causes a slight delay in development that is re£ected in a
reduced accumulation of BmVMP30 protein. Interestingly,
while incubation with the AS-Met1 oligonucleotide has a pro-
nounced e¡ect on the expression of BmVMP30 in follicular
cells and, as described below, causes the disorganization of the
follicular epithelium, developmental progression of the follic-
ular cells through the end of vitellogenesis and into chorio-
genesis was not a¡ected; Western blot analysis showed both
BmGATAL and chorion protein expression in follicular cells
of antisense and inverse oligonucleotide-treated follicles to
remain largely una¡ected relative to untreated follicles (Fig.
4B, middle and right panels).
Because we hypothesized that the 21 kDa protein detected
by the BmVMP30 antibody in follicles that were subjected to
antisense AS-Met1 oligonucleotide treatment may have re-
£ected the use of the fourth methionine codon in the
BmVMP30 ORF, a second antisense oligonucleotide was de-
signed against this ATG codon (AS-Met4; Fig. 1) in an at-
tempt to knock out completely the expression of BmVMP30.
However, we found that the use of AS-Met4 did not a¡ect the
translation of the protein, while in experiments in which AS-
Met1 and AS-Met4 were combined, no additional e¡ects on
BmVMP30 expression could be observed compared to the use
of AS-Met1 alone (data not shown).
To further clarify the mechanism by which AS-Met1 blocks
the expression of BmVMP30 protein, Northern blot analysis
was carried out. As shown in Fig. 4C, the amount of
BmVMP30 mRNA was drastically reduced following treat-
ment with AS-Met1 oligonucleotide, while the levels of a con-
trol mRNA (actin) were una¡ected. The presence of inverse
oligonucleotide, on the other hand, did not result in a reduc-
tion of BmVMP30 mRNA (Fig. 4C). These results indicate
that the AS-Met1 oligonucleotide also reduces the levels of
BmVMP30 mRNA in the follicles, possibly by targeting the
mRNA for degradation by RNaseH [27].
In contrast to follicles incubated either with inverse oligo-
nucleotide or with culture medium alone, follicles cultured in
vitro in the presence of 15 WM antisense oligonucleotide show
a distinct phenotype. As seen in panels 1^3 of Fig. 4D, the
follicular epithelium of follicles incubated with the antisense
oligonucleotide is hardly distinguishable, and the follicle is
held together by the outer basal lamina. Moreover, the oocyte
integrity is compromised, as illustrated by the internal ‘bleed-
ing’ of the yolk within the boundaries of the follicle (panels 1^
3 of Fig. 4D). DAPI-staining of the follicles shows that gaps
exist in the follicular epithelium suggesting that the follicular
cells are no longer arranged in an orderly manner (panel 2 of
Fig. 4E). Immuno£uorescent experiments using BmVMP30
antibodies show that unlike the wild-type protein, the trun-
cated BmVMP30 protein that is induced following antisense
nucleotide treatment (Fig. 4A,B) is unable to localize at the
junction between the follicular cells and the oocyte (compare
panel 4 with panel 3 in Fig. 4E). Rather, the £uorescent signal
derived from truncated BmVMP30 protein remains di¡used
throughout the cytoplasm of the follicular cells (panel 4 of
Fig. 4E). The accumulation into the cytoplasm can be ex-
plained by the lack of an N-terminal signal peptide sequence
in vBmVMP30 resulting from the blockage of the ¢rst trans-
lation initiation codon of the BmVMP30 ORF by the anti-
sense oligonucleotide AS-Met1. Finally, staining with tubulin
antibodies con¢rms the loss of the follicular epithelium’s
structural integrity in follicles-treated with the antisense oli-
gonucleotide (panel 6 of Fig. 4E). By contrast, no distinguish-
able phenotype could be discerned in follicles cultured in the
presence of the inverse oligonucleotide (panels 4 and 5 of Fig.
4D) relative to untreated follicles (panels 6 and 7 of Fig. 4D).
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DAPI-staining as well as imuno£uorescent detection of
BmVMP30 and tubulin in inverse oligonucleotide-treated fol-
licles also did not show any irregularities in the organization
of the follicular epithelium (panels 1, 3 and 5 of Fig. 4E).
4. Discussion
To understand the developmental program that is initiated
at mid-vitellogenesis and results in the autonomous implemen-
tation of choriogenesis in the follicular epithelium [5], a M/
LV-RNA-enriched cDNA library was di¡erentially screened
for the presence of cDNAs whose mRNAs become expressed
during stages 330 and later of follicular development. Our
screen resulted in the isolation of the cDNA encoding a novel
protein of 30 kDa, BmVMP30.
Our data show that BmVMP30 becomes incorporated into
the silkmoth eggshell, most likely as a component of the VM.
The expression pattern of BmVMP30 and its subfollicular
localization during oogenesis and after egg-laying agrees
very well with the predicted behavior of VMPs. BmVMP30
mRNA levels are high during the middle/late stages of vitello-
genesis but become subsequently undetectable in choriogenic
follicles (Fig. 2A,B) such that the entire pool of BmVMP30
must be synthesized by the end of vitellogenesis. This behavior
is reminiscent of the Drosophila VMPs, which are expressed
during a narrow window of oogenesis, S9-S10 (prior to egg-
shell synthesis) and constitute the entire pool of VMPs for the
rest of development [7,28,29]. After translation, BmVMP30
protein is secreted outside the epithelial cells toward the oo-
cyte because it remains associated with the egg after ovula-
tion, i.e. after removal of the follicular epithelium that syn-
thesizes BmVMP30. Immunolocalization studies point to the
concentration of BmVMP30 in the intercellular junction be-
tween follicular cells as well as at the oocyte^follicular epithe-
lium interface (Figs. 3C and 4E, panel 3) and, in Western blot
analysis, BmVMP30 is found in total eggshell extracts as well
as isolated VMs from follicles and mature eggs (Fig. 3B,D;
data not shown). Most notably, chorion extracts contain
BmVMP30 immunoreactive proteins of higher molecular
weight, which probably re£ect the cross-linking of BmVMP30
either to itself or to other proteins that are incorporated in the
eggshell (Fig. 3D).
During vitellogenesis, a functional VM is not formed in the
follicles as it would not allow transport of the yolk proteins to
the oocyte. In Drosophila, VM components accumulate ini-
tially between oocyte and follicular epithelium as small
vesicles, the vitelline bodies, and formation of a functional
VM is initiated just prior to choriogenesis through vesicle
fusion and hardening [7]. Thus, the presence of BmVMP30
in the intercellular spaces between the follicular cells and the
oocyte in vitellogenic follicles (Figs. 3C and 4E, panel 3) likely
re£ects its secretion by the follicular cells and its subsequent
accumulation in similar vitelline bodies before the formation
of a functional membrane at the termination of vitellogenesis.
The ¢nding that BmVMP30 becomes undetectable upon
fertilization is in agreement with its role as a VM component.
It is well known that immediately after fertilization, an exten-
sive reorganization occurs at the oocyte surface and that the
‘fertilization membrane’ is formed [30]. Electron microscopy
studies have shown that an extensive rearrangement of the
VM also takes place following sperm entry in Bombyx egg,
culminating in the formation of the fertilization membrane
[31]. Besides secretion of new material by the oocyte, changes
in the VM following fertilization seem to involve also proteo-
lytic processing or degradation of its components. Proteolytic
processing of BmVMP30 may result in loss of the hydrophilic
region at the N-terminus and loss of the epitopes recognized
by the antibody used in our studies.
In dipteran insects, the characterized VMPs are proline,
serine, glycine and alanine rich [8]. They possess an N-termi-
nal hydrophobic region believed to act as a signal peptide and
contain a highly conserved 38 AA hydrophobic core domain
(VM domain) towards the C-terminus [32]. This region is so
highly conserved that cross-hybridization between the genes
can be achieved [32,33]. The small genes encoding these pro-
teins also lack introns [7]. Although BmVMP30 does not have
signi¢cant sequence identity with dipteran VMPs, including
the VM domain that is conserved among Diptera (data not
shown), it does share with them a distinct overall proline
distribution, a signal peptide, a similar general hydropathy
pro¢le and the lack of introns in the gene structure (Fig. 1).
BmVMP30 does not become expressed in ovaries that are
induced by the ecdysone agonist RH-5992 (Fig. 2A, right
panel). Because treatment with RH-5992 causes persistent ec-
dysone signaling in the follicles, it induces a developmental
arrest at stages requiring a decline in ecdysone signaling for
their further development. Thus, BmVMP30 belongs to the
class of genes in the ecdysone regulatory hierarchy that are
expressed following a decline of ecdysone titer in the hemo-
lymph. It is possible that BmVMP30 expression is induced by
BmFTZ-F1, a nuclear receptor that is known to be induced
during falling ecdysone titers and is expressed in ovarian fol-
licles concomitantly with BmVMP30 [24].
When the hormonal regulation of BmVMP30 is compared
with that of the dipteran VMs, it appears that, in contrast to
the situation in Bombyx, the mosquito VM 15a genes are
induced by ecdysteroids in vivo and in vitro [33,34]. This
probably re£ects di¡erences between the mosquito and the
silkmoth regarding the general control of ovarian develop-
ment by 20E [24,35].
Antisense oligonucleotide inhibition of gene function [9]
shows that BmVMP30 is required for the maintenance of
follicle integrity. The disruption of the integrity of the follic-
ular epithelium and oocyte by inhibition of BmVMP30 func-
tion (Fig. 4D,E) can be explained by the concomitant disrup-
tion of the VM which provides a skeletal support for both cell
types during the assembly of the eggshell at choriogenesis.
However, the basal lamina remained intact and kept the fol-
licle from disintegrating. This result reinforces the hypothesis
that BmVMP30 is associated with the oocyte membrane and
the follicular epithelium and that it is essential for the con-
nection between follicular epithelium and oocyte.
The phenotype observed by treating Bombyx follicles with
antisense oligonucleotide directed against BmVMP30 di¡ers
from the phenotype observed for VMP mutants in Drosophila.
In null mutants for the VMP sV23, no e¡ects on the integrity
of the follicle were reported [7,8] although the mutant eggs
developed collapsed eggshells that were infertile [36]. These
observations indicate that a functional VM is not required
in Drosophila for maintaining the structure of the follicle
but rather that it provides an initial sca¡old for chorion as-
sembly and micropyle formation for fertilization. However,
Bombyx follicles are much larger than those of Drosophila
and may need additional support to maintain their integrity.
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More speci¢cally, in Bombyx there is a large uptake of water
by the oocyte in a short period just prior to choriogenesis [1]
and this may require the formation of a robust VM by the
follicular epithelium.
Antisense oligonucleotide inhibition of BmVMP30 function
appears to result in the production of a truncated protein,
vBmVMP30 (Fig. 4A,B). The truncated protein may have
arisen from the usage of an internal ATG start codon after
the ¢rst methionine codon is blocked by the antisense oligo-
nucleotide and therefore is predicted to lack the N-terminal
signal peptide (Fig. 1). BmVMP30 immunoreactive material
accumulates in the cytoplasm of cells of the follicular epithe-
lium of follicles treated with antisense oligonucleotide, there-
fore, the protein does not seem to be secreted in this case (Fig.
4E, panel 4). Besides inhibition of translation, antisense
oligonucleotides also have an e¡ect on the amount of
BmVMP30 mRNA present in follicular cells (Fig. 4C).
Thus, oligonucleotide-mediated inhibition of gene function is
carried out in silkmoth ovarian follicles (in vitro) according in
two ways, i.e. inhibition of translation initiation and targeted
RNA degradation.
Although structurally compromised, follicles expressing
truncated BmVMP30 are able to complete their vitellogenic
development and enter choriogenesis, as seen by the expres-
sion of the late vitellogenic marker BmGATAL and early
chorion proteins (Fig. 4B). This was not totally unexpected
as silkworm egg development mutants generally complete oo-
genesis [37]. Thus, the integrity of the follicle does not a¡ect
the function of the follicular epithelium, as it progresses nor-
mally through the developmental program in vitro. Experi-
ments could not be pursued for longer than 48 h because of
the fragility of the BmVMP30 antisense treated follicles.
Therefore, the long-term e¡ects on the development of fol-
licles and eggs (e.g. completion of choriogenesis) could not
be assessed.
The isolation and functional characterization of BmVMP30
re£ects our e¡orts to isolate and analyze genes expressed after
the commitment stage for follicular cells and required for the
initiation and completion of the long-term developmental pro-
gram of choriogenesis. While BmVMP30 was shown not to be
involved in the implementation of this autonomous program,
e¡orts are currently underway to characterize its gene pro-
moter (Fig. 1), a ¢rst step toward the isolation of regulatory
factors expressed during the late stages of vitellogenesis.
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